首页>投融资
Epic Sciences
E~PreIPO
Epic Sciences Inc is a developer of liquid biopsy diagnostics to guide therapy selection and monitor disease progression to personalize the treatment and management of prostate and breast cancer.In April 2023, Epic Sciences Inc had completed $24 million Series G and $43 million Series F financing.In June 2022, Epic Sciences Inc had completed a $43 million first close of its Series F financing
基本信息
-
公司全称Epic Sciences Inc
-
类型液体活检及癌症治疗技术研发商
-
产业领域试剂/耗材、器械/设备
-
公司人数101~500人
-
地址9381 Judicial Dr Ste 200 SAN DIEGO CALIFORNIA 92121-3832; US; Telephone: +18583566610;
-
联系电话858-356-6610
-
邮箱info@epicsciences.com
-
成立时间2008-01-01
投融资
-
2023-04-15E~PreIPO2400万美元DOMAINBlue Ox Healthcare PartnersDeerfieldArsenal Capital PartnersLabCorp Venture Fund
-
2022-06-01E~PreIPO4300万美元Blue Ox Healthcare PartnersDeerfieldArsenal Capital PartnersLabCorp Venture Fund
-
2018-09-12E~PreIPO5200万美元Alexandria Venture InvestmentsDOMAINBlue Ox Healthcare PartnersDeerfieldSabby ManagementVarian Medical SystemsViventuresAltos Capital Partners
-
2017-04-28D轮4000万美元Sabby Capital
-
2015-06-01债权融资1500万美元美国硅谷银行
-
2014-07-30C轮3000万美元辉瑞Roche Venture FundDOMAINArcus Ventures
-
2012-11-03B轮1300万美元DOMAINReach Tone LimitedRMI PartnersAltos Capital Partners弘励创投
- 加载更多
相关投融资企业
收并购
Becton, Dickinson and Co is a medical technology company with a particular emphasis on diagnostics and disposables.In July 2022, Becton, Dickinson and Co acquired MedKeeper.In April 2022, Becton, Dickinson and Co had completed its spinoff of Embecta Corp.In February 2022, Becton, Dickinson and Co had announced the sale of Cytognos by Vitro SA. Later that month, the company acquired Cytognos Sl completely.In December 2021, the company had acquired Tissuemed Ltd. Later that month, the company announced it completed the acquisition of Scanwell Health Inc.In November 2020, BD had acquired the medical business assets of CUBEX.In September 2018, Thermo Fisher Scientific had entered into a definitive agreement to acquire advanced bioprocessing business of BD Technologies.In July 2005, Becton Dickinson had agreed to sell its Clontech Laboratories Inc unit to Takara Bio for $60 million, The plan to sell Clontech had a
增发
Establishment Labs Holdings Inc.于2013年10月9日在英属维尔京群岛的母公司控制下重组。该公司是一家医疗技术公司，专注于改善患者的安全和美学结果，最初是在乳房美学和重建市场。公司的硅胶填充乳房植入物系列，品牌为Motiva Implants，是医疗技术平台的核心。该公司还开发了其他补充产品和服务，旨在进一步提高患者的治疗效果。
B轮
星辰海医疗成立于2020年10月，是一家专注于内窥镜介入诊疗业务的医疗科技公司，旨在向全球提供涵盖泌尿、呼吸、消化等科室的内窥镜介入诊疗整体解决方案，让疾病更早被发现，让患者更好被治疗。内窥镜诊疗是非血管微创介入的重要组成部分，广泛分布于消化科、泌尿科、呼吸、耳鼻喉科、普外科以及妇科等。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息